Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on May 9, 2025

A groundbreaking discovery of a common master switch to cure Alzheimer’s, Parkinson’s, and other brain-related diseases
A breakthrough that could save millions of lives NEW YORK, NY, UNITED STATES, May 9, 2025 /EINPresswire.com/ -- The 21st edition of Sustainability Through Science and Technology Summit 2025 (SIPS 2025), dedicated to Prof. Aaron Ciechanover, Nobel …

Amerigo Scientific Announces Cell Proliferation and Viability Assay Kits to Unlock Precision in Cell Research
NEW YORK, NY, UNITED STATES, May 9, 2025 /EINPresswire.com/ -- In today’s fast-moving world of cell biology, there is a need for reliable and reproducible analysis of cell proliferation and viability to progress research in drug discovery, cancer studies …

Restoration Health 365 Opens in Jericho, NY, Bringing Personalized Health Optimization and Advanced Testing
Drs. Lawrence Kessler …

Samuel Waxman Cancer Research Foundation to Hold 11th Annual Luncheon 2025
Honoring Susan Pernick and Featuring a Live Fashion Presentation of the AKRIS Spring/Summer 2025 collection NEW YORK, NY, UNITED STATES, May 9, 2025 /EINPresswire.com/ -- The 11th Annual Waxman Luncheon, benefiting the Samuel Waxman Cancer Research …

Activists Mark Luigi Mangione’s Birthday With Aerial Protest as Times Square Billboard on Jury Rights Explodes Online
Image by POPNYC NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Two major public actions are unfolding in New York City this week to highlight systemic injustice in both the healthcare and criminal legal systems. Though independently organized, both coincide …

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that it will present full 12 …

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient …

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences
DRAPER, Utah, May 09, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its first quarter of fiscal 2026 financial …

Theriva Biologics anuncia el cierre de una oferta pública de 7,5 millones de dólares
ROCKVILLE, Maryland, May 09, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en …

Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal fluid administration in non-human primates Data …

Publication relative à des notifications de transparence
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 9 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations …

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …

Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings …

Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast …

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and …

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration …

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash and restricted cash balance …

Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, …

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee …

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …